Literature DB >> 5826877

[Contribution to the diagnosis and clinical picture of malignant reticulosis of the skin].

H W Kreysel, M Gerlach, U Hermanns.   

Abstract

Entities:  

Mesh:

Year:  1965        PMID: 5826877

Source DB:  PubMed          Journal:  Arch Klin Exp Dermatol        ISSN: 0300-8614


× No keyword cloud information.
  24 in total

Review 1.  [RESULTS OF CHEMOTHERAPY OF HEMOBLASTOSES WITH VINBLASTINE AND VINCRISTINE SULFATE].

Authors:  K E HAMPEL; H GERHARTZ
Journal:  Krebsforsch Krebsbekampf       Date:  1964

2.  [Pathomorphology of reticular tissue with special reference to lipomelanotic reticulosis].

Authors:  H MEESSEN
Journal:  Hautarzt       Date:  1955-01       Impact factor: 0.751

3.  [Reticulosarcomatosis based on acrodermatitis chronica atrophicans & blood protein studies in blastomatous reticulohistocytary disorders of the skin].

Authors:  W KNOTH
Journal:  Hautarzt       Date:  1958-10       Impact factor: 0.751

4.  [Skin reticulosis (histio-monocytic reticulosis)].

Authors:  R Degos; B Ossipovski; J Civatte; R Touraine
Journal:  Ann Dermatol Syphiligr (Paris)       Date:  1957 Mar-Apr

5.  [Reticulohistiocytosis of the skin].

Authors:  A MUSGER
Journal:  Hautarzt       Date:  1954-02       Impact factor: 0.751

6.  [Grave polymorphic erythema; Stevens-Johnson syndrome, revealing acute malignant reticulosis; histiomonocytoid leukosis].

Authors:  C GRUPPER; P KARTUN; B ELISALDE
Journal:  Bull Soc Fr Dermatol Syphiligr       Date:  1953 Jan-Feb

7.  [Not Available].

Authors:  P CAZAL
Journal:  Sem Hop       Date:  1948-04-02

8.  [Clinical and hematological aspects of malignant reticulosis].

Authors:  P CAZAL
Journal:  Acta Haematol       Date:  1952-02       Impact factor: 2.195

9.  [Clinical picture of reticuloses, with special references to sensitization studies by means of paraprotein forms].

Authors:  S MOESCHLIN
Journal:  Helv Med Acta       Date:  1961-09

10.  Cutaneous manifestations of the reticuloses.

Authors:  B RUSSELL
Journal:  Br J Radiol       Date:  1951-09       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.